Total reported value
$215.4M
Reporting period: 2026-03-31 · Number of holdings: 24
NEXTBio Capital Management LP disclosed 24 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $215.4M and a quarterly turnover rate of 32.0%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "N"
Trim ZBIO
+32.5% -$3.3M
Trim VSTM
-0.0% -$3.2M
Add STTK
0.0% $8.8M
Add CMPS
+168.6% $6.0M
Add 430
+9.7% $9.6M
Trim CMPX
-23.9% -$1.5M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | 430 | Terns Pharmaceuticals INC | Stock-Other | 14.80% | +1.74% | +9.68% | |
| 2 | PTGX | Protagonist Therapeutics INC | Stock-Other | 11.24% | -0.52% | — | |
| 3 | STTK | Shattuck Labs INC | Stock-Other | 9.40% | +2.66% | — | |
| 4 | VOR | Vor Biopharma INC | Stock-Other | 8.28% | +0.61% | — | |
| 5 | CMPS | Compass Pathways PLC | Stock-Other | 5.19% | +2.14% | +168.58% | |
| 6 | RYTM | Rhythm Pharmaceuticals INC | Stock-Other | 5.09% | +0.85% | +86.54% | |
| 7 | XENE | Xenon Pharmaceuticals INC | Stock-Other | 4.95% | +0.12% | -0.26% | |
| 8 | PVLA | Palvella Therapeutics INC | Stock-Other | 4.79% | -0.29% | — | |
| 9 | ZBIO | Zenas Biopharma INC | Stock-Other | 3.87% | -2.99% | +32.53% | |
| 10 | IVA | Inventiva SA - Adr | Stock-Other | 3.44% | -0.10% | +2.68% | |
| 11 | VSTM | Verastem INC | Stock-Other | 3.22% | -2.70% | -0.04% | |
| 12 | ✓ | Crescent Biopharma INC. | Stock-Other | 3.18% | +0.59% | — | |
| 13 | ORIC | Oric Pharmaceuticals INC | Stock-Other | 3.08% | +0.13% | -14.96% | |
| 14 | GPCR | Structure Therapeutics INC | Stock-Other | 2.98% | -0.87% | +41.08% | |
| 15 | PCVX | Vaxcyte INC | Stock-Other | 2.57% | -0.01% | -0.27% | |
| 16 | COGT | Cogent Biosciences INC | Stock-Other | 2.34% | +0.34% | +36.91% | |
| 17 | CMPX | Compass Therapeutics INC | Stock-Other | 2.08% | -1.43% | -23.86% | |
| 18 | EVMN | Evommune INC | Stock-Other | 1.96% | -0.33% | -19.37% | |
| 19 | OCS | Oculis Holding AG | Stock-Other | 1.85% | +0.10% | -0.11% | |
| 20 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 1.60% | -0.09% | +12.24% | |
| 21 | IRON | Disc Medicine INC | Stock-Other | 1.56% | -0.43% | +23.09% | |
| 22 | 4XC1 | Kalvista Pharmaceuticals INC | Stock-Other | 1.23% | -0.02% | — | |
| 23 | SMMT | Summit Therapeutics INC | Stock-Other | 0.79% | +0.79% | NEW | |
| 24 | ACET | Adicet Bio INC | Stock-Other | 0.50% | -0.28% | — |
Performance for Q3 2026
+16.7%
Performance Last 4 Quarters
+19.8%
Based on 5 months of available history
Based on 70% of reported portfolio value with available pricing
Not enough sector-mapped data yet
NEXTBio Capital Management LP's most significant position changes for 2026-03-31: New buy: Summit Therapeutics INC (SMMT); Add: Zenas Biopharma INC (ZBIO) — shares +32.53%; Trim: Verastem INC (VSTM) — shares -0.04%; Add: Compass Pathways PLC (CMPS) — shares +168.58%; Add: Terns Pharmaceuticals INC (430) — shares +9.68%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | STTK | Shattuck Labs INC | +2.7% | — | Unchanged |
| 2 | CMPS | Compass Pathways PLC | +2.1% | +168.58% | Add |
| 3 | 430 | Terns Pharmaceuticals INC | +1.7% | +9.68% | Add |
| 4 | RYTM | Rhythm Pharmaceuticals INC | +0.9% | +86.54% | Add |
| 5 | VOR | Vor Biopharma INC | +0.6% | — | Unchanged |
| 6 | ✓ | Crescent Biopharma INC. | +0.6% | — | Unchanged |
| 7 | COGT | Cogent Biosciences INC | +0.3% | +36.91% | Add |
| 8 | ORIC | Oric Pharmaceuticals INC | +0.1% | -14.96% | Trim |
| 9 | XENE | Xenon Pharmaceuticals INC | +0.1% | -0.26% | Trim |
| 10 | OCS | Oculis Holding AG | +0.1% | -0.11% | Trim |
| 11 | PCVX | Vaxcyte INC | 0% | -0.27% | Trim |
| 12 | 4XC1 | Kalvista Pharmaceuticals INC | 0% | — | Unchanged |
| 13 | ZLAB | Zai Lab Ltd-adr | -0.1% | +12.24% | Add |
| 14 | IVA | Inventiva SA - Adr | -0.1% | +2.68% | Add |
| 15 | ACET | Adicet Bio INC | -0.3% | — | Unchanged |
| 16 | PVLA | Palvella Therapeutics INC | -0.3% | — | Unchanged |
| 17 | EVMN | Evommune INC | -0.3% | -19.37% | Trim |
| 18 | IRON | Disc Medicine INC | -0.4% | +23.09% | Add |
| 19 | PTGX | Protagonist Therapeutics INC | -0.5% | — | Unchanged |
| 20 | GPCR | Structure Therapeutics INC | -0.9% | +41.08% | Add |
| 21 | CMPX | Compass Therapeutics INC | -1.4% | -23.86% | Trim |
| 22 | VSTM | Verastem INC | -2.7% | -0.04% | Trim |
| 23 | ZBIO | Zenas Biopharma INC | -3% | +32.53% | Add |
| 24 | SMMT | Summit Therapeutics INC | — | NEW | New buy |
Institutions with a similar AUM
CIK 0002070972
Total reported value
$215.4M
269 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001659718
Total reported value
$215.4M
74 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0002033094
Total reported value
$215.4M
141 stks
2026-06-30
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0001940272
Total reported value
$1.7B
311 stks
2026-03-31
2 of the top 5 holdings overlap, including Protagonist Therapeutics INC
CIK 0000200406
Total reported value
$652.4M
16 stks
2026-03-31
1 of the top 5 holdings overlap, including Protagonist Therapeutics INC
CIK 0000924020
Total reported value
$978.2M
21 stks
2021-06-30
Stale — no recent filing
1 of the top 5 holdings overlap, including Protagonist Therapeutics INC